1-3 of 3
Keith C. Lantz, MS
Close
Sort by
Journal Articles

Impact of Baseline Free Light Chain Ratio (rFLC) On Clinical Outcomes and Change in rFLC During Treatment in Patients with Relapsed/Refractory Multiple Myeloma Treated with Pegylated Liposomal Doxorubicin Plus Bortezomib or Bortezomib Alone.

Valeria Magarotto, MD, Anil Londhe, PhD, Keith C. Lantz, MS, Colin Lowery, DPhil, Pieter Sonneveld, MD, PhD, Joan BladeĢ, MD, Jean-Luc Harousseau, MD, Robert Z. Orlowski, MD, PhD
Journal: Blood
Blood (2009) 114 (22): 4778.
https://doi.org/10.1182/blood.V114.22.4778.4778
Published: 2009
Journal Articles

The Effect of Paraprotein Heavy Chain and Free Light Chain Types on the Efficacy of Pegylated Liposomal Doxorubicin + Bortezomib Versus Bortezomib Alone in Patients with Relapsed/Refractory Multiple Myeloma

Jatin Shah, MD, Joan Blade, MD, Pieter Sonneveld, MD, PhD, Jesus San Miguel, MD, Donghan Luo, PhD, Keith C Lantz, MS, Colin Lowery, PhD, Jean-Luc Harousseau, MD, Robert Z. Orlowski, MD, PhD
Journal: Blood
Blood (2008) 112 (11): 5190.
https://doi.org/10.1182/blood.V112.11.5190.5190
Published: 2008
Journal Articles

The Effect of Bone Marrow Involvement on the Efficacy of Pegylated Liposomal Doxorubicin + Bortezomib Vs Bortezomib Alone in Patients with Relapsed/Refractory Multiple Myeloma

Jatin Shah, MD, Joan Blade, MD, Jesus San Miguel, MD, Pieter Sonneveld, MD, PhD, Donghan Luo, PhD, Keith C Lantz, MS, Colin Lowery, PhD, Jean-Luc Harousseau, MD, Robert Z. Orlowski, MD, PhD
Journal: Blood
Blood (2008) 112 (11): 5192.
https://doi.org/10.1182/blood.V112.11.5192.5192
Published: 2008